Skip to main content
Equibles
BNGO logo

BNGO · Bionano Genomics, Inc.

Track BNGO — free

Use BNGO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.27 +0.05 (+4.26%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has prepared cash flows forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the six months ended June 30, 2026, are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$14.37M
Shares
11.78M

BNGO metrics

64 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.22
Market cap
$14.37M

Price action

19 metrics
Price change (1W)
-2.4%
Price change (30D)
+8.9%
Price change (3M)
-3.2%
Price change (6M)
+8.9%
Price change (YTD)
-20.3%
Price change (1Y)
-67.6%
Trailing year
Price change (5Y)
—
52-week high
$4.92
52-week low
$1.06
Change from 52-week high
-75.2%
Change from 52-week low
+15.1%
Annualized volatility
77.7%
Beta
1.5
RSI (14D)
56.5
Price vs SMA 50
+5.7%
Price vs SMA 200
-5.0%
Avg volume (3M)
137,029
Relative volume
1.5
Average dollar volume
$159,846

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
11.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 210.0%
P / book
0.5
reciprocal yield 220.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-223.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
59.4×
reciprocal yield 1.7%
EV / revenue historical average (5Y)
59.4×
reciprocal yield 1.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
47.5%
Operating margin
-106.7%
Trailing 12 months
Net margin
-106.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$32.19M
Net income (TTM)
−$32.16M
Trailing 12 months
Diluted EPS (TTM)
$-3.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-390,078.91

Growth

11 metrics
Revenue growth YoY
+21.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$30.18M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+235.5%
Year over year · more shares
Revenue CAGR (3Y)
+0.8%
Revenue CAGR (5Y)
+27.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-101.8%
Return on assets
-67.6%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
−$22.87M
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.73M
Total assets
$47.59M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.48M
Capital expenditures (TTM)
$344,000
R&D (TTM)
$12.20M
SG&A (TTM)
$34.33M
Stock compensation (TTM)
$3.51M
R&D / revenue
40.4%
Stock compensation / revenue
11.6%

Ownership (13F)

3 metrics
13F filers
34
13F filer change QoQ
+2
Institutional ownership
6.0%

Short interest

3 metrics
Short interest
9.8%
Latest settlement · 8.7 days to cover
Days to cover
8.7d
Short-squeeze score
83 / 100

Insider activity

2 metrics
Net insider buying (90D)
$4,860
Insider-sentiment score
76 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1411690 CUSIP 09075F404 13F (30d) 32 filings 32 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)